News und Analysen

On November 13, New York City-based Hyperion Capital Advisors disclosed a new position in Vertex (NASDAQ:VERX), acquiring 540,000 shares valued at approximately $13.39 million.

According to a filing

Shares in Agios Pharmaceuticals (NASDAQ: AGIO) soared by more than 18% as of 11 a.m. today. The move follows the company's receipt of approval from the Food and Drug Administration (FDA) for AQVESME

Novo Nordisk (NYSE:NVO), which develops and markets diabetes and obesity treatments, closed Tuesday’s session at $51.61, up 7.30% after U.S. approval of its once-daily oral Wegovy weight-loss pill

New York City-based Horizon Kinetics Asset Management disclosed a new position in WaterBridge Infrastructure LLC (NYSE:WBI), acquiring about 6.35 million shares valued at $160.26 million, per a

New York City-based Horizon Kinetics Asset Management reported a buy of 133,188 shares of LandBridge Company LLC (LB), while the position value decreased by $71.14 million, per a November 14 SEC

In today's video, I discuss recent updates affecting Nvidia (NASDAQ: NVDA), Advanced Micro Devices (NASDAQ: AMD), and other AI stocks. To learn more, check out the short video, consider subscribing,

Shares of Novo Nordisk (NYSE: NVO) surged after the company introduced its GLP-1 weight loss drugs to the market. Investors correctly recognized the desirability of a weight loss drug, but, as often

Investing in dividend stocks is a proven way to grow wealth. Over the last 50 years, dividend stocks have delivered more than double the average annual total return compared to non-dividend payers,

A decade ago, Advanced Micro Devices (NASDAQ: AMD) was in a difficult position. Revenue fell 28% in 2015, primarily due to declining processor sales, and the company posted a net loss of $660

Pfizer (NYSE: PFE) and Merck (NYSE: MRK) are two pharmaceutical giants that have lagged broader equities this year. Both have delivered unimpressive financial results recently, and are facing a

B. Lynne Parshall, Director at Cytokinetics, Incorporated (NASDAQ:CYTK), reported the sale of 5,000 shares in an open-market transaction valued at ~$323,650 on November 19, 2025; direct ownership

CRISPR Therapeutics (NASDAQ: CRSP) has had a volatile performance over the past five years. While its stock is up more than 40% this year, in three of the past five years it has fallen by more than

When it comes to famous investment personalities, names such as Warren Buffett or Jamie Dimon usually get mentioned first. In the world of hedge funds, though, Ken Griffin is the cream of the crop.

Valuations for many stocks are sky-high, and that can make now an unappealing time to invest in the stock market. However, there are still some great value buys that don't involve taking on a lot of

UnitedHealth Group (NYSE: UNH) and Eli Lilly (NYSE: LLY) are two of the largest and most powerful healthcare companies in the world. One is a juggernaut that provides insurance, care services, and

AbbVie (NYSE: ABBV) is an investment that is full of contradictions. It has a strong pharmaceutical business, but the third quarter of 2025 was terrible on the earnings front. It has an attractive

Is the S&P 500 due for a crash next year? That's a big question on the minds of many investors these days. Concerns about bubbles in tech and overall high valuations for the stock market have many

Investing in up-and-coming growth stocks can involve risk, but doing so can also result in tremendous returns if things go well. It all comes down to taking calculated risks and investing in stocks

Pfizer (NYSE: PFE) and Eli Lilly (NYSE: LLY) are two prominent names in healthcare that have focused on innovation and growing their respective businesses for decades. But in recent years, it's been

In today's video, I discuss recent updates affecting Advanced Micro Devices (NASDAQ: AMD) and other AI stocks. To learn more, check out the short video, consider subscribing, and click the special

No one knows how the stock market will unfold in 2026. Perhaps broader equities will experience significant volatility but perform well by the end of the year, just as they seem to be doing in 2025

New York City-based DSC Meridian Capital initiated a new position in Elme Communities (NYSE:ELME), acquiring 543,081 shares valued at approximately $9.2 million, according to a November 14 SEC